The global sales of antidiabetics are estimated to be worth USD 106.3 billion in 2024 and anticipated to reach a value of USD 298.2 billion by 2034. Sales are projected to rise at a CAGR of 10.9% over the forecast period between 2024 and 2034. The revenue generated by Antidiabetics in 2023 was USD 97.3 billion.
The antidiabetic market is amongst the fastest-growing pharmaceutical markets; the demand in this market is driven by the increase in global prevalence of diabetes. Antidiabetics address blood glucose management through several therapeutic modalities: oral, insulin therapies, and now emerging biologics.
Major growth factors in this industry include increasing awareness and the development of new drugs. These include an increase in diabetic patients as a result of changes in lifestyles and the growth in population with age, which demands the development and approval of new and efficient antidiabetic therapies.
All these factors are a result of continuous research and technological advancements being carried out for improvement in patient outcomes and diabetes management, which, in turn, acts as a driver for the market growth.
Global Antidiabetics Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 97.3 billion |
| Estimated Size, 2024 | USD 106.3 billion |
| Projected Size, 2034 | USD 298.2 billion |
| Value-based CAGR (2024 to 2034) | 10.9% |
Awareness and diagnosis are the main factors driving the antidiabetic market, while growing awareness of managing diabetes conditions has made people more conscious about early diagnosis and getting timely treatments. This trend is further boosted by educational campaigns, health screenings, and outreach programs that underscore the risks related to diabetes and how effective management leads to benefits.
Early diagnosis is important, whereby this has prepared a way for timely intervention-that is very important in preventing disease progression and thus reducing complications. The patients diagnosed early are likely to adhere to prescribed treatments and lifestyle modifications, which leads to better management of their condition and, therefore, an increasing demand for antidiabetic medications arises, hence driving market growth.
This, in turn, often increases health screenings and resultant diagnoses, further increasing diagnosed incidence. This increases demand for current treatments and spurs the development and utilization of new therapies. In all, better awareness of diabetes and its management is translating into not only increased diagnoses but also better adherence to treatment regimens-hence, an overall strong and growing market for antidiabetic drugs.
The growth of biosimilars is one of the main trends observable in the antidiabetic market as they are less expensive copies of original biologic insulin products. Biologics, being highly similar to existing biologics yet more affordable, thus present a good opportunity to save healthcare cost and provide more patient access to insulin therapies.
Upon the expiration of patents on original biologic insulins, the entry of biosimilars opens up competition that drives down prices. This trend helps the patients by providing cheaper modes of treatment, but it also benefits the market due to the broadening of product portfolios and innovation in diabetes management.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global antidiabetics market's compound annual growth rate (CAGR) for the first half of 2023 and 2024 is compared in the table below. This analysis provides important insights into the performance of the industry by highlighting significant shifts and trends in revenue generation.
The first half (H1) is the period from January to June, and the second half (H2) is July to December. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 12.1%, followed by a slightly lower growth rate of 11.6% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 12.1% (2023 to 2033) |
| H2 | 11.6% (2023 to 2033) |
| H1 | 10.9% (2024 to 2034) |
| H2 | 10.6% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 10.9% in the first half and remain relatively moderate at 10.6% in the second half. In the first half (H1) the industry witnessed a decrease of 120 BPS while in the second half (H2), the industry witnessed a decrease of 100 BPS.
Increasing rates of type 1 and type 2 diabetes globally drives the market growth
Rise in prevalence of diabetes is the primary growth factor for the market. In light of rising incidences of diabetes due to genetic propensity, bad lifestyle habits, and an aging population, there is a greater demand for more active solutions against diabetes.
Type 1 diabetes is a chronic but less common form of the disorder that needs to be addressed through constant administration of insulin in the form of lifelong therapy, coupled with the continuous development of newer modes of treatment.
Of the two types, the more prevalent form of the disease, type 2 diabetes, is associated with obesity and inactivity. It drives a large portion of the market due to its increasing prevalence through diverse age groups and regions. According to the data provided in January 2022, by International Diabetes Federation, globally there were over 537 million diabetic patients in 2021 and that is estimated to grow to 783 million by 2045.
Similarly, as per the data provided by CDC on May 15, 2024, there were around 38.4 million people living with diabetes in USA in year 2021.
Improved awareness about diabetes management and early diagnosis is boosting the industry growth
Improvement in awareness and diagnosis acts as the major growth factor to the antidiabetic market, improving medication adherence and market demand. Growing awareness among people and healthcare professionals regarding the risks and management of diabetes has ushered in more proactive attitudes toward health with frequent screenings.
Educational programs, media campaigns, and community outreach also play a key role in the enlightenment of people regarding diabetes, symptoms, and the need for early intervention.
Diagnosis done early is very useful because there is timely management of the condition that can allow preventing or delaying complications. A greater number of people are being diagnosed at earlier stages of diabetes, thus increasing demand for effective treatment options. Thus, the demand for antidiabetic medications increases and, therefore, market growth.
With better awareness, there is increased patient compliance to prescribed treatment regimen. There would be better understanding on the part of the patients of the importance of effective management of diabetes; this would improve their adherence to medication schedules and also to lifestyle recommendations.
Improved adherence brings about better patient outcomes, in addition to increasing the demand for a broad range of antidiabetic therapies, therefore adding to the overall market growth.
In all, growing awareness, together with early diagnosis, acts synergistically to enhance the antidiabetic market through better medication adherence and increasing demand with respect to diabetes management solutions.
Shift towards non-insulin therapies is a major trend in the market
The current major trend in the antidiabetic market is toward non-insulin treatments, owing to the greater demand for the oral route of administration and non-insulin injectable. The convenience of treatment and more patient-friendly modality is a major driving factor.
Oral antidiabetic agents, such as metformin, are being supplemented with newer agents such as SGLT2 inhibitors and GLP-1 receptor agonists, which circumvent the invasiveness of insulin injections.
Patients often prefer these therapies because of ease of administration and reduced need for frequent monitoring compared to insulin. Other novel classes and injectable, including GLP-1 receptor agonists, show increased acceptance.
These injectable formulations generally require less frequent dosing and are endowed with a number of desirable properties that include weight reduction and cardiovascular protection; hence, these are an attractive option for many patients.
The ease and convenience associated with the use of these therapies enhance patient adherence and overall satisfaction with diabetes management. This shift is in line with wider trends toward patient-centered care and personalized medicine, emphasizing treatments that would fit seamlessly into the lifestyles of patients and improve the quality of life.
High cost of medications may restrict market growth
The high price of medications remains one of the high points of restraints faced by the antidiabetic market, especially in low-income regions. Most antidiabetic therapies have expensive price components, from advanced insulin products to newer classes, which not all people can afford either because of a lack of resources or insufficient insurance schemes.
This maintains barriers to access, leading to disparities in diabetes care and management.
These patients, who are usually constrained financially, may not be in a position to afford their drugs, thus compromising their living conditions, adherence to treatment schedules, and the poor management of their diseases. This may further deteriorate health conditions, creating more complications that might worsen further with continuous financial burdens placed on individuals and health systems.
Besides, high medication costs contribute to the general healthcare disparity, reducing access to effective diabetes management in economically deprived regions. Thus, high cost of anti-diabetic drugs is expected to act as a major restraining factor to the industry’s growth.
Principal Consultant
The global antidiabetics industry recorded a CAGR of 8.6% during the historical period between 2019 and 2023. The growth of antidiabetics industry was positive as it reached a value of USD 298.2 billion in 2034 from USD 106.3 billion in 2024.
Throughout history, dietary control and early insulin therapy were the two major pillars in the management of diabetes, starting in the 1920s. Insulin injections tended to be crude, with blood glucose monitoring confined to occasional tests. The treatment options were few and far between, with minimal patient education.
In contrast, today's diabetes management employs sophisticated tools and therapies. Continuous glucose monitors, insulin pumps, and a wide range of oral and injectable drugs interfere with several different diabetes mechanisms. Treatment has also become more tailored by incorporating lifestyle changes and digital health initiatives that can provide more specific and effective management for the disease while providing better quality of life.
Development of new drugs is the major driving force in the anti-diabetic market, increasing efficacy and personalization of treatment. More recent innovations have brought in newer classes: GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors-which target different mechanisms of blood glucose control.
These newer therapies offer superior glycemic control with ancillary benefits, such as reduction of body weight and protection against CVDs. Combination therapies have similarly mushroomed, offering much more comprehensive treatment by simultaneously targeting numerous pathways.
These combinations assure greater efficacy and fewer drugs to be taken. Moreover, the new modes of drug formulation and delivery, including extended-release formulations and injectable other than insulin, improve patient compliance and convenience.
Personalized medicine, with its increased knowledge in genomics and biotechnology, provides profiles of individual patients in order to tailor treatment to better manage the disease more precisely. These two forces combined drive growth within the market by increasing treatment options and improving patient outcomes.
Tier 1 companies are the industry leaders with a revenue of more than USD 100 million, or 41.7% of the global industry. These companies stand out for having a large product portfolio and a high production capacity.
These industry leaders also stand out for having a wide geographic reach, a strong customer base, and substantial experience in manufacturing and having enough financial resources which enables them to enhance their research and development efforts and expand into new industries.
The companies within tier 1 have a good reputation and high brand value. These companies frequently get involved in strategies such as acquisition and product launches. Prominent companies within tier 1 include AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, and Novo Nordisk
Tier 2 companies are relatively smaller as compared with tier 1 players. The tier 2 companies hold a market share of 29.7% worldwide. These firms may not have cutting-edge technology or a broad global reach, but they do ensure regulatory compliance and follows cGMP.
The players are more competitive when it comes to pricing and target regional markets. Key Companies under this category include Johnson & Johnson, Merck & Co. Inc., and Novartis AG.
Compared to Tiers 1 and 2, Tier 3 companies offer antidiabetic drugs, but with smaller revenue spouts and less influence. These companies mostly operate in one or two countries and have limited customer base.
The companies such as Halozyme Therapeutics, Oramed Pharmaceuticals Inc., Pfizer, Sanofi, Takeda Pharmaceutical and others falls under tier 3 category. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market analysis for antidiabetics in various nations is covered in the section below. An analysis of important nations in North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East and Africa (MEA) has been mentioned below.
It is projected that the USA will maintain its leading position in North America through 2034, holding a value share of 80.6%. By 2034, China is expected to experience a CAGR of 11.6% in the Asia-Pacific region.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| USA | 5.2% |
| Germany | 6.8% |
| France | 7.6% |
| UK | 8.3% |
| China | 11.6% |
| India | 12.6% |
| South Korea | 9.7% |
Germany’s antidiabetics market is poised to exhibit a CAGR of 6.8% between 2024 and 2034. The Germany holds highest market share in European market.
Key growth factors in the antidiabetic market are the advances in drug development that have so far provided immense growth in the management of diabetes within Germany. New drug classes being introduced to the market, such as GLP-1 receptor agonists and SGLT2 inhibitors, are revolutionizing treatments toward more specific ways of managing blood glucose.
Along with their glucose-lowering effects, these newer therapies offer additional benefits of weight loss and cardiovascular protection, overall enhancing outcomes in patients.
Combination therapies involving multiple drug mechanisms allow for a wider approach toward managing diabetes, thereby increasing efficacy while minimizing adverse effects. Support through the use of genomics and biotechnology allows personalized treatment plans by providing tailored therapies to meet the unique profile of each patient, further optimizing the management of disease.
These factors are particularly strong in Germany because of the well-established health infrastructure and high levels of research investment, allowing for a more rapid diffusion of novel therapies. The outcomes of these factors enhance the scope of treatment and raise care quality for diabetes patients, which also contributes to market growth.
The USA is anticipated to show a CAGR of 5.2% between 2024 and 2034.
In the USA, increasing prevalence of diabetes acts as a major growth factor for the antidiabetic market. The prevalence of type 1 and type 2 diabetes has increased due to changes in lifestyle, which includes bad eating habits and not taking enough exercise or living a sedentary life, along with the increasing obese population. The aging population further exaggerates the situation because age increases the risk of diabetes.
This growing number of diabetes cases makes the demand for efficient management solutions, like drugs, monitoring devices, and support care, rise. With the prevalence increasing, it means that there are more individuals in the need for antidiabetic therapies-thus giving this market a boost for growth.
The necessity to manage the increasing disease load reinforces the focus on advanced treatments and new ideas of management strategies. The USA market, in turn, responds to the demand with an increase in investment in research and development, creating newer and better antidiabetic options and thus improving outcomes.
China is anticipated to show a CAGR of 11.6% between 2024 and 2034.
The growing interest in insulin biosimilars in China plays a massive role in the antidiabetic market. Diabetes continues to rise due to urbanization, lifestyle changes, and an aging population, thus pushing demand for cheaper diabetes management options. Biosimilars of insulin are a more affordable option to an originator biologic insulin product; hence, they really do lower the cost burden on patients and health systems considerably.
While their entry into the market should increase the level of competition, prices go down, increasing access to people who would have had high costs. The Chinese government is also supporting this transition through regulatory policies coupled with market incentives that favor biosimilars.
This favorable environment increases not only treatment adherence but also the market reach of antidiabetic therapies. Therefore, the rising inclination toward biosimilars of insulin remains as one of the major factors driving up the growth in the antidiabetic market of China.
| Product | Insulin-based Antidiabetics |
|---|---|
| Value Share (2024) | 55.6% |
The Insulin-based Antidiabetics segment is projected to be a dominating segment in terms of revenue, accounting for almost 55.6% of the market share in 2024.
The insulin-based antidiabetics segment will hold a major share in the market, because it plays an important role in both type-1 and type-2 diabetes management for patients with greater needs for enhanced glucose management.
Insulin remains the cornerstone of diabetes therapy, with continuous advancements in developing new insulin analogs, delivery devices, and biosimilars that further optimize efficacy and patient compliance. The high incidence of diabetes and continuous development of technologies related to insulin further sustained the dominance of this segment by continuing to drive demand.
In addition, the critical need for appropriate blood glucose management further solidifies insulin-based products into an indispensable modality of treatment for diabetes.
| Route of Administration | Oral |
|---|---|
| Value Share (2024) | 54.7% |
The oral segment will dominate the industry in terms of revenue, accounting for almost 54.7% of the market share in 2024.
The oral segment is going to dominate the market for antidiabetic drugs, since they are most acceptable and easy to use, thus showing high patient compliance. The oral drugs, like metformin, and newer agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, are more acceptable and easy to manage than the injectable therapies.
This makes them more compliant and consequently more acceptable in a greater number of patients. In addition, the oral antidiabetics provide effective glycemic control and are well-positioned for the treatment of type 2 diabetes, which further drives their popularity.
This trend goes in line with the emerging increase of oral therapies, which is in support of the advancement in the development of drugs that favor patients to prefer them and their dominance in the market.
The antidiabetics industry faces a high competition as there are large number of antidiabetic drug manufacturers. These manufacturers are focused on constantly innovating and improving their product portfolio.
Prominent producers of antidiabetic drug market are concentrating on growing internationally in order to increase their revenue and increase the size of their sales footprint in developing nations through the acquisition of regional small players. Manufacturers utilize various key strategies such as agreements, product launches, research sponsorship, and strategic collaborations to boost product sales and establish their market presence.
Recent Industry Developments in Antidiabetics Market
In terms of product, the industry is divided into insulin-based antidiabetics (rapid-acting analog, long-acting analog, premixed insulin, short-acting analog, intermediate-acting insulin) and antidiabetics drug class (alpha-glucosidases inhibitors, biguanides, sulphonylureas, GLP-1 (glucagon-like peptide) agonists, DPP-IV (dipeptidyl peptidase) inhibitors, meglitinides, SGLT-II (sodium-glucose transport proteins) inhibitors and thiazolidinedione)
In terms of patient population, the industry is segregated into antidiabetics for pediatrics, antidiabetics for adults, and antidiabetics for geriatrics
In terms of route of administration, the industry is divided into oral, intravenous, insulin syringes/ insulin pens, insulin pumps and others
In terms of distribution channel, the industry is divided into hospitals, clinics, retail pharmacies, drug stores, and online sales
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East and Africa (MEA) have been covered in the report.
The global antidiabetics industry is projected to witness CAGR of 10.9% between 2024 and 2034.
The global antidiabetics industry stood at USD 97.3 billion in 2023.
The global antidiabetics industry is anticipated to reach USD 298.2 billion by 2034 end.
China is expected to show a CAGR of 11.6% in the assessment period.
The key players operating in the global antidiabetics industry AstraZeneca, Bayer Corporation, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Halozyme Therapeutics,Johnson & Johnson, Merck & Co. Inc., Novartis AG, Novo Nordisk, Oramed Pharmaceuticals Inc., Pfizer, Sanofi, Takeda Pharmaceutical
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis, 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis, and Future Projections 5. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034 5.1. By Product 5.2. By Patient Population 5.3. By Route of Administration 5.4. By Distribution Channel 5.5. By Region 6. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Product 6.1. Insulin-based Antidiabetics 6.1.1. Rapid-Acting Analog 6.1.2. Long-Acting Analog 6.1.3. Premixed Insulin 6.1.4. Short-Acting Analog 6.1.5. Intermediate-Acting Insulin 6.2. Antidiabetics Drug Class 6.2.1. Alpha-Glucosidase Inhibitors 6.2.2. Biguanides 6.2.3. Sulphonylureas 6.2.4. GLP-1 (Glucagon-like Peptide) Agonists 6.2.5. DPP-IV (Dipeptidyl Peptidase) Inhibitors 6.2.6. Meglitinides 6.2.7. SGLT-II (Sodium-Glucose Transport Proteins) Inhibitors 6.2.8. Thiazolidinedione 7. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Patient Population 7.1. Antidiabetics for Pediatrics 7.2. Antidiabetics for Adults 7.3. Antidiabetics for Geriatrics 8. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration 8.1. Oral 8.2. Intravenous 8.3. Insulin Syringes/ Insulin Pens 8.4. Insulin Pumps 8.5. Others 9. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel 9.1. Hospitals 9.2. Clinics 9.3. Retail Pharmacies 9.4. Drug Stores 9.5. Online Sales 10. Global Market Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. East Asia 10.4. South Asia and Pacific 10.5. Western Europe 10.6. Eastern Europe 10.7. Middle East and Africa 11. North America Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. East Asia Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. South Asia & Pacific Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Western Europe Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Eastern Europe Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East and Africa Sales Analysis, 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Product, Patient Population, Route of Administration and Distribution Channel for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis, by Key Players, and Competition Dashboard 20. Company Profile 20.1. AstraZeneca 20.2. Bayer Corporation 20.3. Boehringer Ingelheim 20.4. Bristol-Myers Squibb 20.5. Eli Lilly 20.6. Halozyme Therapeutics 20.7. Johnson & Johnson 20.8. Merck & Co. Inc. 20.9. Novartis AG 20.10. Novo Nordisk 20.11. Oramed Pharmaceuticals Inc. 20.12. Pfizer 20.13. Sanofi 20.14. Takeda Pharmaceutical
Explore Healthcare Insights
View Reports
Antidiabetics Market
